ATE400301T1 - Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen - Google Patents

Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen

Info

Publication number
ATE400301T1
ATE400301T1 AT96912854T AT96912854T ATE400301T1 AT E400301 T1 ATE400301 T1 AT E400301T1 AT 96912854 T AT96912854 T AT 96912854T AT 96912854 T AT96912854 T AT 96912854T AT E400301 T1 ATE400301 T1 AT E400301T1
Authority
AT
Austria
Prior art keywords
arteriovenous
compositions
methods
compounds
extracellular matrix
Prior art date
Application number
AT96912854T
Other languages
English (en)
Inventor
Andrew Zalewski
Yi Shi
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE400301T1 publication Critical patent/ATE400301T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96912854T 1995-04-19 1996-04-19 Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen ATE400301T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/424,991 US6323184B1 (en) 1993-10-15 1995-04-19 Arteriovenous and venous graft treatments: methods and compositions

Publications (1)

Publication Number Publication Date
ATE400301T1 true ATE400301T1 (de) 2008-07-15

Family

ID=23684702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912854T ATE400301T1 (de) 1995-04-19 1996-04-19 Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen

Country Status (15)

Country Link
US (1) US6323184B1 (de)
EP (1) EP0871496B1 (de)
JP (1) JP3958362B2 (de)
KR (1) KR19990007864A (de)
CN (1) CN1177615C (de)
AT (1) ATE400301T1 (de)
AU (1) AU714658B2 (de)
BR (1) BR9608454A (de)
CA (1) CA2215631A1 (de)
CZ (1) CZ295039B6 (de)
DE (1) DE69637593D1 (de)
HU (1) HU225244B1 (de)
NO (1) NO974824L (de)
PL (1) PL188628B1 (de)
WO (1) WO1996032966A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3981416B2 (ja) 1997-04-10 2007-09-26 ユニバーシティ メディカル センター ナイメーヘン Ｐｃａ３タンパク質、ｐｃａ３遺伝子、及びこれらの用途
KR20010102992A (ko) * 1999-01-29 2001-11-17 추후보정 표적 ｒｎａ를 검출하는 비-침입적 방법
US6709465B2 (en) 1999-03-18 2004-03-23 Fossa Medical, Inc. Radially expanding ureteral device
US7214229B2 (en) 1999-03-18 2007-05-08 Fossa Medical, Inc. Radially expanding stents
PT1222266E (pt) 1999-09-29 2006-07-31 Diagnocure Inc Arn mensageiro de pca3 em tecidos benignos e malignos da prostata
EP1263484B1 (de) * 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Beschichtung welche ein anhaften von endothelzellen stimuliert
EP1351681B1 (de) * 2001-01-16 2010-09-15 Vascular Therapies, LLC Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7144381B2 (en) * 2001-06-20 2006-12-05 The Regents Of The University Of California Hemodialysis system and method
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7893248B2 (en) * 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
AU2003213203A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incorporated Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
DK1638624T3 (da) 2003-06-19 2014-02-03 Vascular Therapies Llc Vaskulær lukkeindretning
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
EP2231229A1 (de) 2007-12-18 2010-09-29 Insuline Medical Ltd. Wirkstofffreisetzungsvorrichtung mit sensor für geschlossenen kreislauf
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
KR20110086132A (ko) 2008-11-07 2011-07-27 인슐린 메디컬 엘티디 약물 전달 장치 및 방법
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5122048A (en) 1990-09-24 1992-06-16 Exxon Chemical Patents Inc. Charging apparatus for meltblown webs
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5756476A (en) * 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5869462A (en) * 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994015943A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
WO1994015645A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
CN1119830A (zh) 1993-01-07 1996-04-03 托马斯·杰弗逊大学 反义抑制C-myc以调节平滑肌细胞的增殖
JPH08511530A (ja) 1993-06-11 1996-12-03 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 内因性酸化窒素生成又は活性の調節による血管変性疾患の治療
JPH09503790A (ja) 1993-10-15 1997-04-15 トーマス ジェファーソン ユニバーシティ 核原発ガン遺伝子に向けられたアンチセンス化合物による細胞外マトリクス合成の阻害

Also Published As

Publication number Publication date
CZ295039B6 (cs) 2005-05-18
KR19990007864A (ko) 1999-01-25
JPH11503911A (ja) 1999-04-06
NO974824D0 (no) 1997-10-17
HUP9800729A2 (hu) 1998-07-28
US6323184B1 (en) 2001-11-27
HUP9800729A3 (en) 2000-07-28
PL323046A1 (en) 1998-03-02
EP0871496B1 (de) 2008-07-09
EP0871496A1 (de) 1998-10-21
AU714658B2 (en) 2000-01-06
CN1177615C (zh) 2004-12-01
EP0871496A4 (de) 1998-10-21
BR9608454A (pt) 2002-02-05
DE69637593D1 (de) 2008-08-21
CN1181706A (zh) 1998-05-13
CA2215631A1 (en) 1996-10-24
JP3958362B2 (ja) 2007-08-15
HU225244B1 (en) 2006-08-28
CZ330297A3 (cs) 1998-03-18
PL188628B1 (pl) 2005-03-31
NO974824L (no) 1997-12-16
AU5553296A (en) 1996-11-07
WO1996032966A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
DE69637593D1 (de) Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
NO20002788D0 (no) Nye forbindelser
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69525279D1 (de) Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE69526216D1 (de) Antifungaleverfahren und mitteln
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
ES2138734T3 (es) Procedimiento para la preparacion de derivados de 1-(3-trialquilsililfenil)-2,2,2-trifluormetil etanona.
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties